| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Leukocyte Membrane Protein Laboratory and
Vaccine Development and Infectious Diseases Laboratory, Austin Research Institute, Victoria, Australia;
Novartis Pharmaceutical, Muttenz, Switzerland;
Institute of Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany;
¶
Department of Immunology and Cell Biology, Research Center Borstel, Borstel, Germany; and
||
Department of Molecular Genetics, Institute of Molecular Pharmacology, Free University of Berlin, Berlin, Germany
CD37 is a leukocyte-specific protein belonging to the tetraspanin superfamily. Previously thought to be predominantly a B cell molecule, CD37 is shown in this study to regulate T cell proliferation. CD37-deficient (CD37-/-) T cells were notably hyperproliferative in MLR, in response to Con A, or CD3-TCR engagement particularly in the absence of CD28 costimulation. Hyperproliferation was not due to differences in memory to naive T cell ratios in CD37-/- mice, apoptosis, or TCR down-modulation. Division cycle analyses revealed CD37-/- T cells to enter first division earlier than wild-type T cells. Importantly, proliferation of CD37-/- T cells was preceded by enhanced early IL-2 production. We hypothesized CD37 to be involved in TCR signaling and this was supported by the observation that CD4/CD8-associated p56Lck kinase activity was increased in CD37-/- T cells. Remarkably, CD37 cross-linking on human T cells transduced signals that led to complete inhibition of CD3-induced proliferation. In the presence of CD28 costimulation, CD37 engagement still significantly reduced proliferation. Taken together, these results demonstrate a regulatory role for CD37 in T cell proliferation by influencing early events of TCR signaling.
This article has been cited by other articles:
|
|
 |
|
  X. Zhao, R. Lapalombella, T. Joshi, C. Cheney, A. Gowda, M. S. Hayden-Ledbetter, P. R. Baum, T. S. Lin, D. Jarjoura, A. Lehman, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical Blood, October 1, 2007; 110(7): 2569 - 2577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Williams Drosophila Hemopoiesis and Cellular Immunity J. Immunol., April 15, 2007; 178(8): 4711 - 4716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Meyer-Wentrup, C. G. Figdor, M. Ansems, P. Brossart, M. D. Wright, G. J. Adema, and A. B. van Spriel Dectin-1 Interaction with Tetraspanin CD37 Inhibits IL-6 Production J. Immunol., January 1, 2007; 178(1): 154 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Graff, M. Behnke, J. Radke, M. White, and M. A. Jutila A comprehensive SAGE database for the analysis of {gamma}{delta} T cells Int. Immunol., April 1, 2006; 18(4): 613 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Pouniotis, O. Proudfoot, V. Bogdanoska, K. Scalzo, S. Kovacevic, R. L. Coppel, and M. Plebanski Selectively Impaired CD8+ but Not CD4+ T Cell Cycle Arrest during Priming as a Consequence of Dendritic Cell Interaction with Plasmodium-Infected Red Cells J. Immunol., September 15, 2005; 175(6): 3525 - 3533. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
